Listen, folks, we’ve got this incredible new technology, the TEG6s, it’s fantastic, really fantastic. It’s for checking blood clotting in adults right at the bedside – can you believe it? But we didn’t know, we just didn’t know how well it worked for the kids, the little ones going through heart surgery. So, we did this huge study, a big one, at a single center, with all these kids, from tiny babies to teenagers, who had heart surgery between August 2020 and November 2022.

We took their blood, a lot of blood, before and after they were on this heart-lung machine, and we checked it with the TEG6s and the old-school lab method. And let me tell you, we had over 400 cases, a lot of data, and we found out that before the surgery, the TEG6s, it was a bit too generous, always saying there was more fibrinogen than there actually was – we’re talking about a difference of 138 mg/dL on average. But after the surgery, it got better, much better, almost right on the money, except for the newborns, where it was a little off.

And the accuracy, it was fair, not perfect, but fair, with some good numbers for the infants. We even figured out the best numbers to use to predict if these kids would have low fibrinogen after surgery. So, it looks like the TEG6s, it could be a real game-changer for these young patients, a real lifesaver. But, and this is important, we’ve got to be careful, very careful, because it’s not perfect. We’ve got to use it right, or it won’t work the way we want it to. Still, it’s a big step, a huge step for pediatric heart surgery. Believe me, it’s going to be great.